Health benefits of oral contraceptives

Obstetrics and Gynecology Clinics of North America

Volumn 27, Issue 4, 2000, Pages 705-721

  Jensen, Jeffrey T ^b   Speroff, Leon ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

ACNE; BONE DENSITY; COLORECTAL CANCER; CONTRACEPTION; DRUG EFFECT; DRUG INDICATION; ECTOPIC PREGNANCY; ENDOMETRIUM CANCER; IRON DEFICIENCY ANEMIA; MENSTRUATION DISORDER; OVARY CANCER; OVARY POLYCYSTIC DISEASE; PELVIC INFLAMMATORY DISEASE; PRIORITY JOURNAL; REVIEW; UTERUS MYOMA;

EID: 0033768040     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8545(05)70169-8     Document Type: Article

References (85)

1. Fertility, family planning, and women's health: New data from the 1995 National Survey of Family Growth
2. The reduction in risk of ovarian cancer associated with oral contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development
3. The evaluation and management of acne: Economic considerations
4. Oral contraceptives and rheumatoid arthritis: Results from a primary care-based incident case-control study
5. Risk factors for benign breast disease
6. The role of oral contraceptives in the treatment of hyperandrogenic disorders
7. Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne: Results of a multicenter study
8. Effects of sex steroids on skin 5 alpha-reductase activity in vitro
9. Prostaglandin levels in menstrual fluid of nomdysmenorrheic and of dysmenorrheic subjects with and without oral contraceptive or ibuprofen therapy
10. Oral contraceptive use and risk of benign breast disease in a French case-control study of young women
11. Use of oral contraceptives and uterine fibroids: Results from a case-control study
12. Acute adolescent menorrhagia
13. Clinician/patient interaction: Communicating the benefits and risks of oral contraceptives
14. Dysmenorrhea
15. Ovulation inhibitors containing cyproterone acetate or desogestrel in the treatment of hyperandrogenic symptoms
16. Oral contraceptive use and risk of colorectal cancer
17. Menstrual migraine: Methods of prevention and control
18. Oral contraceptives and colorectal tumors: A review of epidemiologic studies
19. Longitudinal evaluation of perimenopausal vertebral bone loss: Effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism
20. Haemoperitoneum caused by haemorrhagic corpus luteum in a patient with type 3 von Willebrand's disease
21. Ovulation and follicular development associated with three low-dose oral contraceptives: A randomized controlled trial
22. The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer
23. Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer
24. Bone mineral density in young women with long-standing amenorrhea: Limited effect of hormone replacement therapy with ethinyl estradiol and desogestrel
25. A quantitative assessment of oral contraceptive use and risk of ovarian cancer
26. Unintended pregnancy in the United States
27. Bone mineral changes in young women with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone, or placebo over 12 months
28. Functional ovarian cysts in relation to the use of monophasic and triphasic oral contraceptives
29. Deaths: Final data for 1997
30. Oral contraceptive pills for heavy menstrual bleeding
31. Oral contraceptive health benefits: Perception versus reality
32. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: Its central role in explaining and predicting endometrial cancer risk
33. Oral contraceptive use may protect against low bone mass. Henry Ford Hospital Osteoporosis Cooperative Research Group
34. Epidemiology of adolescent dysmenorrhea
35. Bone mineral density in postmenopausal women as determined by prior oral contraceptive use
36. Oral contraceptive type and functional ovarian cysts
37. The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status
38. The pill and the press: Reporting risk
39. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethinyl estradiol and d,1-norgestrel
40. The effect of oral contraceptive use on vertebral bone mass in pre- and postmenopausal women
41. Hormonal correlates of acne and hirsutism
42. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris
43. Clinical and hormonal effects of ethinyl estradiol combined with gestodene and desogestrel in young women with acne vulgaris
44. A prospective study of reproductive factors, oral contraceptive use, and risk of colorectal cancer
45. A case of menstruation-associated asthma: Treatment with oral contraceptives
46. Oral contraceptive use and risk of hip fracture: A case-control study
47. Iron status in 268 Danish women aged 18-30 years: Influence of menstruation, contraceptive method, and iron supplementation
48. The influence of different combined oral contraceptives on the prevalence and severity of dysmenorrhea
49. Modern combined oral contraceptives for pain associated with endometriosis
50. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group
51. Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives
52. Type of oral contraceptive in relation to acute, initial episodes of pelvic inflammatory disease
53. Contraceptive methods and risk of pelvic endometriosis
54. Oral contraceptive risk assessment: A survey of 247 educated women
55. The health effects of oral contraceptives: Misperceptions, controversies, and continuing good news
56. Familial ovarian cancer: A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991
57. Controversy of oral contraceptives and risk of rheumatoid arthritis: Meta-analysis of conflicting studies and review of conflicting meta-analyses with special emphasis on analysis of heterogeneity
58. How effective are contraceptives? The determination and measurement of pregnancy rates
59. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: A randomized, placebo-controlled trial
60. Differences in risk factors for epithelial ovarian cancer by histologic type: Results of a case-control study
61. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer
62. Risk factors for uterine fibroids: Reduced risk associated with oral contraceptives
63. Epidemiology of endometriosis among parous women
64. Risk of endometrial cancer in relation to use of combined oral contraceptives: A practitioner's guide to meta-analysis
65. Hormone replacement therapy in perimenopausal women with a triphasic contraceptive compound: A three-year prospective study
66. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas
67. The epidemiology of polycystic ovary syndrome: Prevalence and associated disease risks
68. The prevalence of acne on the basis of physical examination
69. Factors influencing the prevalence and severity of dysmenorrhoea in young women
70. Perceptions of contraceptive effectiveness and health effects of oral contraception
71. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women?
72. The use of oral contraceptives by adolescents for contraception, menstrual cycle problems or acne
73. Endometrial and ovarian cancer and oral contraceptives - Findings in a large cohort study
74. Epidemiology of endometriosis in women attending family planning clinics
75. Cost of and payment source for pelvic inflammatory disease: Trends and projections, 1983 through 2000
76. Effect of two low-dose oral contraceptives on androgens and acne
77. Clinical experience with triphasic oral contraceptive (Triquilar) in 527 women in China
78. Characteristics relating to ovarian cancer risk: Implications for prevention and detection
79. A survey of adolescent dysmenorrhea and premenstrual symptom frequency: A model program for prevention, detection, and treatment
80. An open study of Triphasil and Diane 50 in the treatment of acne
81. A randomized, double-blind, placebo-controlled comparison of the impact of low-dose and triphasic oral contraceptives on follicular development